Drug Development Tools: Passed And Future
FDA has qualified a total of eight biomarkers submitted by two different consortia through a process that has followed, to varying degrees, the route described in the recently released draft guidance on drug development tool qualification.
You may also be interested in...
The firms that obtained FDA/EMEA qualification of seven nephrotoxicity biomarkers for preclinical drug testing are midway through development of a protocol to test their efficacy in a clinical trial
The company seeks to keep Makena on the market with a narrower indication while it conducts a new randomized, controlled trial in the US, but the FDA’s drugs center says keeping the drug on the market would render a new trial infeasible and do a disservice to women at risk for preterm birth.
The four-hour virtual public meeting featured "incompatible" views of the FDA and sponsor on the OCEAN data, not to mention signs of impatience and resentment, with each side criticizing the positions of the other over the safety and efficacy of the multiple myeloma drug.